News

SummaryAL amyloidosis is caused by a plasma cell clone that produces abnormal light chains that misfold and deposit as amyloid fibrils in tissues and thus affect…

AbstractCardiac involvement is the main determinant of prognosis in immunoglobulin light-chain (AL) amyloidosis, but may be under-recognized in patients with…

BridgeBio Pharma reports first-quarter earnings after the market close Thursday, with investors focused on the commercial trajectory of Attruby, the company’s…

AbstractBackgroundAL amyloidosis is a rare systemic disorder related to plasma cell dyscrasias and caused by deposition of monoclonal light chains. Cardiac…

AbstractBackgroundIn patients with suspected amyloid cardiomyopathy (CM) and a monoclonal protein, tissue biopsy is mandatory to exclude amyloid light–chain CM (AL–…

AbstractIntroductionTafamidis is the cornerstone therapy for transthyretin amyloid cardiomyopathy (ATTR–CM); however, validated criteria for monitoring disease…

Investigational PET tracer Iodine 124 Evuzamitide from Bayer meets primary endpoints in Phase III study in patients suspected to have cardiac amyloidosisMay 7…

The oral therapy acoramidis has been approved in Brazil, to be sold as Beyonttra, for treating adults with hereditary or wild-type transthyretin amyloid…

Armed with new phase 3 data, Bayer is preparing to file for approval of a new PET imaging agent that could accelerate the diagnosis of diseases associated with the…

BERLIN & WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced positive topline results from the Phase III REVEAL study, an investigator-initiated study by…